EdgeNode and AI for Drug Innovation Association Partner to Build Saudi Arabia’s First Pharmaceutical Executable Digital Twin

EdgeNode and the AI for Drug Innovation Association have launched a strategic joint research and development initiative in Riyadh to construct an executable digital twin of the Kingdom of Saudi Arabia's pharmaceutical innovation ecosystem, bridging AI molecular discovery with clinical, regulatory, and localized manufacturing execution.

RIYADH, Saudi Arabia — September 15, 2026 — EdgeNode, a provider of executable digital twins and deterministic process simulation solutions, and the AI for Drug Innovation Association (جمعية بالذكاء الاصطناعي نبتكر الدواء), a Saudi nonprofit organization dedicated to advancing artificial intelligence across healthcare and biopharma, today announced a joint research and development partnership to develop an executable digital twin for the pharmaceutical research and development ecosystem in the Kingdom of Saudi Arabia.

Bridging AI Discovery to Operational Execution

While generative AI models continue to accelerate computational drug discovery, downstream stages—including preclinical workflows, clinical operations, regulatory approvals, and localized biomanufacturing—frequently encounter delays caused by resource dependencies, fragmented stakeholder handoffs, and complex compliance gates.

The joint force pairs the Association’s regional life-sciences networks and domain leadership with EdgeNode’s semantic modeling engine to construct an integrated, testable architecture of the entire pharmaceutical pipeline.

"Our mandate is to turn artificial intelligence into tangible therapies that reach patients faster. Building an executable digital twin of our innovation ecosystem provides our researchers, healthcare clusters, and investors with an operational flight simulator to test pathways, expose bottlenecks, and validate regulatory readiness before committing capital." — Dr. Abdulmohsen Alrohaimi, Chairman of the AI for Drug Innovation Association

"AI drug discovery generates exceptional scientific hypotheses, but those hypotheses must survive the logistical and regulatory complexities of clinical trials and production. EdgeNode provides the simulation backbone that lets teams mathematically prove operational feasibility before committing physical resources." — Ivan.S. Kretov, General Director of LLC EdgeNode

Key Discussion Topics

• Executable Systems Modeling: Transforms static workflow diagrams into mathematically verified, executable models that simulate operational bottlenecks, processing latency, and capacity constraints.
• Clinical Trial Protocol Optimization: Simulates patient cohorts, site capacities, and logistical dependencies across Saudi healthcare clusters prior to site activation.
• Domestic Biomanufacturing Resilience: Applies Value Stream Mapping (VSM) and scenario analysis to local active pharmaceutical ingredient (API) synthesis and cold-chain logistics.
• Data Sovereignty by Design: Supports browser-based collaborative SaaS as well as full on-premise, air-gapped deployments in compliance with SDAIA and National Data Management Office (NDMO) standards.

Strategic Contribution to Saudi Vision 2030

The collaboration directly supports the Kingdom’s Health Sector Transformation Program (HSTP) and Vision 2030 objectives by modernizing digital health infrastructure, cultivating domestic biotech talent through interactive educational sandboxes, and advancing national self-sufficiency in medicine manufacturing.

About the AI for Drug Innovation Association

The AI for Drug Innovation Association (جمعية بالذكاء الاصطناعي نبتكر الدواء) is a Saudi nonprofit organization dedicated to integrating artificial intelligence and data-driven methods into pharmaceutical development. The Association operates across the Kingdom to connect universities, research institutes, healthcare providers, and regulatory authorities to build domestic capacity, accelerate clinical trials, and advance the objectives of Saudi Vision 2030. Learn more at aimedicine.org.sa.

Media Contact